Pharmacogenomics of Heparin-Induced Thrombocytopenia
University of Arizona
125 participants
Mar 1, 2016
OBSERVATIONAL
Conditions
Summary
The purpose of this research is to identify genomic markers that can predict heparin-induced thrombocytopenia (HIT), which is a very serious side effect to heparin. Heparin is commonly used to prevent blood clots and the investigators may be able to identify genomic markers which can be used to prevent heparin use in people who will get HIT.
Eligibility
Inclusion Criteria4
- years of age or older
- Ability to give informed consent
- Have undergone testing for heparin/PF4 antibody with or without SRA testing for HIT
- Have received treatment with unfractionated heparin or low molecular weight heparin (enoxaparin, dalteparin, tinzaparin) prior to antibody or SRA testing
Exclusion Criteria5
- Less than 18 years of age
- Pregnancy
- Hemoglobin less than 9 mg/dL (for larger 5 ounce blood draw)
- Known Human Immunodeficiency Virus (HIV) infection
- Inability to give informed consent
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
A one time blood draw of 150 milliliters will be performed using a vein in the participants arm. Existing venous access will be used for the blood draw in preference of new venipuncture.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT02717039